Evidence map›Paper›PMID 41012598›Full record

ArticleViruses2025

An Anti-HIV Drug Is Highly Effective Against SARS-CoV-2 In Vitro and Has Potential Benefit for Long COVID Treatment.

Saken Khaidarov, Abdul Bari Hejran, Aizhan Moldakaryzova, Slu Izmailova, Bayan Nurgaliyeva, Aizhan Beisenova, Aigul Mustafaeva, Kuanysh Nurzhanova, Yelena Belova, Elmira Satbayeva and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Saken KhaidarovBiology Faculty Building, Department of Biology and Biotechnology, Al-Farabi Kazakh National University, Al-Farabi Street 71, Almaty 050040, Kazakhstan.ORCID 0000-0001-7770-8427
Abdul Bari HejranBiology Faculty Building, Department of Biology and Biotechnology, Al-Farabi Kazakh National University, Al-Farabi Street 71, Almaty 050040, Kazakhstan.ORCID 0009-0000-0443-0305
Aizhan MoldakaryzovaDepartment of Molecular Biology and Medical Genetics, Kazakh National Medical University Named After S.D. Asfendiyarov, Zheltoksan 37A Street, Almaty 050012, Kazakhstan.
Slu IzmailovaSchool of General Medicine 1, Kazakh National Medical University Named After S.D. Asfendiyarov, Tole-bi Street 94, No. 4 Academic Building, Room 206, Almaty 050012, Kazakhstan.
Bayan NurgaliyevaDepartment of Propaedeutics of Internal Medicine, Kazakh National Medical University Named After S.D. Asfendiyarov, Tole-bi Street 94, Almaty 050012, Kazakhstan.ORCID 0000-0003-2555-8644
Aizhan BeisenovaDepartment of Molecular Biology and Medical Genetics, Kazakh National Medical University Named After S.D. Asfendiyarov, Zheltoksan 37A Street, Almaty 050012, Kazakhstan.ORCID 0000-0002-8128-154X
Aigul MustafaevaDepartment of Molecular Biology and Medical Genetics, Kazakh National Medical University Named After S.D. Asfendiyarov, Zheltoksan 37A Street, Almaty 050012, Kazakhstan.
Kuanysh NurzhanovaDepartment of Molecular Biology and Medical Genetics, Kazakh National Medical University Named After S.D. Asfendiyarov, Zheltoksan 37A Street, Almaty 050012, Kazakhstan.
Yelena BelovaDepartment of Propaedeutics of Internal Medicine, Kazakh National Medical University Named After S.D. Asfendiyarov, Tole-bi Street 94, Almaty 050012, Kazakhstan.
Elmira SatbayevaDepartment of Pharmacology, Kazakh National Medical University Named After S.D. Asfendiyarov, Tole-bi Street 94, Almaty 050012, Kazakhstan.ORCID 0000-0002-5521-5776
Askar AidarovDepartment of Oncology, Kazakh-Russian Medical University, Almaty 050012, Kazakhstan.ORCID 0000-0001-5081-1264
Saniya OssikbayevaKazakh Institute of Oncology and Radiology (KazIOR), Almaty 050022, Kazakhstan.ORCID 0000-0003-1420-7486
Yerlan KukubassovKazakh Institute of Oncology and Radiology (KazIOR), Almaty 050022, Kazakhstan.
Jandos AmankulovKazakh Institute of Oncology and Radiology (KazIOR), Almaty 050022, Kazakhstan.ORCID 0000-0001-7389-3119
Tatyana GoncharovaKazakh Institute of Oncology and Radiology (KazIOR), Almaty 050022, Kazakhstan.
Banu YeszhanDepartment of Anatomy, Physiology, and Sports Medicine, Kazakh Academy of Sports and Tourism (KazAST), Abay Street 83/85, Almaty 050022, Kazakhstan.ORCID 0000-0001-8769-5551
Edan TulmanDepartment of Pathobiology and Veterinary Science, Atwater Laboratory, Room A110, University of Connecticut, Storrs, CT 06269, USA.ORCID 0000-0002-2682-5145
Karlygash N TazhibayevaAlmaty Regional Multidisciplinary Clinic, Department of Surgery, Faculty of Medicine and Health, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan.
Assel SadykovaDepartment of General Medical Practice, School of Medicine and Healthcare, Al-Farabi University, Almaty 050040, Kazakhstan.
Nurlan KozhabergenovResearch Institute for Biological Safety Problems, Gvardeyskyi, Kordai 080409, Kazakhstan.ORCID 0000-0001-6299-9399
Yerbol BurashevResearch Institute for Biological Safety Problems, Gvardeyskyi, Kordai 080409, Kazakhstan.ORCID 0000-0002-4701-1992

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The persistent evolution of SARS-CoV-2 necessitates novel antiviral strategies. This study evaluated the anti-HIV prodrugs tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) for repurposing against SARS-CoV-2, assessing key pharmacological indices (CC

Indexed as

AdenineAnti-HIV AgentsAntiviral AgentsCOVID-19 Drug TreatmentSARS-CoV-2TenofovirAlanineAnimalsChlorocebus aethiopsCOVID-19Drug RepositioningHumansVero CellsViral LoadVirus ReplicationAdenineAlanineAnti-HIV AgentsAntiviral AgentsTenofovirtenofovir alafenamideantiviral therapeuticscombination index (CI)cytostatic effect (CE)cytotoxic concentration (CC)drug repurposingin vitro screeningpharmacological indicesSARS-CoV-2synergistic drug combinationstherapeutic window

Identifiers

PMID41012598
PMCPMC12474224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.